Journal: International Journal of Molecular Medicine

Article Title: Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2-positive breast cancer

doi: 10.3892/ijmm.2026.5751

Figure Lengend Snippet: EBA downregulates HER2, p95HER2, HER3 and AKT expression. (A) Immunoblot analysis of HER2, p95HER2 and p-HER2 (Y1221/1222) in JIMT-1 cells treated with EBA for 48 h. (B) Immunoblot analysis of HER3, p-HER3 (Y1289), AKT and p-AKT following treatment with EBA (48 h) in JIMT-1 cells. (C) Immunoblot analysis of HER2, HER3 and EGFR following IP with anti-HER2 antibody in JIMT-1 cells treated with EBA. In silico molecular docking of EBA with the crystal structure of HER2-KD. (D) Surface map of lipophilic and hydrophilic properties at the ATP-binding site of HER2-KD (red, hydrophobic; blue, hydrophilic). (E) 2D interaction diagram showing intermolecular interactions between EBA and HER2-KD. Key amino acid residues within the binding pocket are shown. (F) Predicted binding pose of EBA (purple stick model) within the tyrosine kinase domain of HER2 (blue ribbon). (G) 293T cells were treated with DMSO or EBA for 1 h at 37°C, followed by heating for 3 min. Soluble fractions were collected following centrifugation and analyzed by immunoblotting using an anti-HER2 antibody. EBA, ebastine; p-, phosphorylated; IP, immunoprecipitation; IB, immunoblotting; KD, kinase domain PCB, protein complex binding; TM, transmembrane; a.a., amino acid.

Article Snippet: 293T (American Type Culture Collection) cells were cultured overnight at 37°C in a humidified atmosphere with 5% CO 2 , and treated with either DMSO (vehicle) or 30 μ M ebastine for 1 h at 37°C.

Techniques: Expressing, Western Blot, In Silico, Binding Assay, Centrifugation, Immunoprecipitation

Journal: bioRxiv

Article Title: Bacterial extracellular vesicles indirectly destabilize a human stem cell–derived blood–brain barrier on-chip through pro-inflammatory stimulation of immune cells

doi: 10.64898/2026.01.23.701361

Figure Lengend Snippet: ( a ) Immunofluorescence images of BMECs in a multiwell plate stained for nuclei (blue) and ICAM-1 (magenta) following 16–17 h treatment with 50% hECSR medium + 50% conditioned medium from THP-1 macrophages. The THP-1s had been treated with or without 1×10 8 BEVs ml -1 for 24 h prior to collection of the conditioned medium. ( b ) Barplot of fluorescence intensity of ICAM-1 divided by cell count and normalized to the BMECs exposed to conditioned medium from untreated THP-1s. Performed unpaired two-tailed t-test. ( c ) Immunofluorescence images of BMEC/BPLC co-cultures immunostained for cell nuclei (blue) and claudin-5 (cyan) following 16–17 h treatment with 50% hECSR medium + 50% conditioned medium from THP-1 macrophages. Gaps in claudin-5 staining are circled with dotted lines (yellow). ( d ) Barplot of µSiM co-culture system permeability to lucifer yellow dye. Performed unpaired two-tailed t-test. ( e )–( k ) Cytokine analysis of conditioned medium from THP-1 macrophages that was collected following 24 h treatment with or without 1×10 6 BEVs ml -1 , 1×10 8 BEVs ml -1 , or 10 ng ml -1 LPS. Performed one-way ANOVA with Dunnett post-hoc test for each cytokine. ( e ) Barplot of TNF-α concentration. ( f ) Barplot of IL-1β concentration. ( g ) Barplot of IL-1RA concentration. ( h ) Barplot of IL-2 concentration. ( i ) Barplot of IL-8 concentration. ( j ) Barplot of GM-CSF concentration. ( k ) Barplot of MCP-1 concentration. Scale bars = 100 µm. Error bars = s.d. ✱ = p < 0.05, ✱✱ = p < 0.01, ✱✱✱ = p < 0.001, ✱✱✱✱ = p < 0.0001.

Article Snippet: Human leukemia monocytic type 1 (THP-1) cells (ATCC) were obtained from the lab of Dr. Karin Wuertz-Kozak.

Techniques: Immunofluorescence, Staining, Fluorescence, Cell Characterization, Two Tailed Test, Co-Culture Assay, Permeability, Concentration Assay